Bristol-Myers Squibb Net Tangible Assets

The latest net tangible assets for BMY is $22B as of June 2026. That compares with $63B in the prior-year period — down 64.5% year over year. Investors often review this figure alongside Bristol-Myers Squibb's historical trend and sector peers before judging valuation or financial health.

Over the past year, BMY's net tangible assets moved from $63B to $22B — a 64.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bristol-Myers Squibb's operating scale or balance-sheet position.

A net tangible assets figure of $22B for BMY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BMY's net tangible assets ($22B), review year-over-year change from $63B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Bristol-Myers Squibb's net tangible assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.